- Home
- ACLX
ACLX
Arcellx Inc.
as 09-12-2025 9:36am EST
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 4.1B | IPO Year: | 2022 |
| Target Price: | $114.75 | AVG Volume (30 days): | 538.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.86 - $107.37 | Next Earning Date: | 11-06-2025 |
| Revenue: | $56,979,000 | Revenue Growth: | -60.63% |
| Revenue Growth (this year): | -53.68% | Revenue Growth (next year): | 174.18% |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
BioPharma Dive
22 days ago
Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius
Clinical Trials Arena
3 months ago
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
MT Newswires
3 months ago
Citigroup Initiates Arcellx at Buy With $110 Price Target
Business Wire
4 months ago
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
Insider Monkey
4 months ago
Baron Discovery Fund Initiated a Position in Arcellx (ACLX)
MT Newswires
4 months ago
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise
Business Wire
4 months ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Insider Monkey
4 months ago
Here’s Why Arcellx (ACLX) Declined in Q1
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.